Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Net: 2018-2025

Historic Receivables - Net for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $3.4 million.

  • China SXT Pharmaceuticals' Receivables - Net fell 19.70% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 19.70%. This contributed to the annual value of $3.4 million for FY2025, which is 11.08% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Receivables - Net stood at $3.4 million for FY2025, which was up 11.08% from $3.0 million recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Receivables - Net ranged from a high of $4.8 million in FY2021 and a low of $2.9 million during FY2023.
  • Its 3-year average for Receivables - Net is $3.1 million, with a median of $3.0 million in 2024.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Receivables - Net crashed by 30.00% in 2023, and later rose by 11.08% in 2025.
  • China SXT Pharmaceuticals' Receivables - Net (MRY) stood at $4.8 million in 2021, then fell by 14.27% to $4.1 million in 2022, then crashed by 30.00% to $2.9 million in 2023, then increased by 6.24% to $3.0 million in 2024, then increased by 11.08% to $3.4 million in 2025.
  • Its Receivables - Net was $3.4 million in FY2025, compared to $3.0 million in FY2024 and $2.9 million in FY2023.